Dr. Garrett Vygantas joined Burrill & Company in July of 2006 as a Senior Associate in the Venture Group and is involved in the sourcing, evaluating and structuring new investment opportunities across the life science spectrum. Dr. Vygantas is also a member of the Burrill International Group. He recently co-founded and is the interim CEO of NewBridge Pharmaceuticals, a Dubai-based specialty pharmaceutical company commercializing innovative therapies to treat chronic diseases of increasing incidence (diabetes, obesity, cardiovascular and cancer) and aesthetics in the Middle East, Africa, Turkey and Caspian regions. Before joining Burrill, Dr. Vygantas was with Genentech’s Market Planning Group where he focused on the commercialization and launch of Lucentis for the treatment of wet age-related macular degeneration. Prior to Genentech, Dr. Vygantas worked with retinal specialists in Chicago where he consulted on a variety of diabetes-related ophthalmic imaging projects.

Garrett previously worked at Cowen (Healthcare Investment Banking Group), and EntreMed (Business Development). Garrett serves on the Board of Directors of NewBridge and is a Board Observer on Nora Therapeutics, TRF Pharma, Proventys, and Efficas. He is a Co-Instructor at UCSF’s Center for BioEntrepreneurship’s “Idea to IPO” curriculum and has advised in the formation of numerous start-up biotech companies. Dr. Vygantas completed his Transitional Residency at the University of Pennsylvania and holds MD & MBA degrees from Georgetown University, as well as a B.S. in Biochemistry from Boston College.

Garrett is a member of the Kauffman Fellows Program.